The publication of the pricing and reimbursement decision for Pepaxti (melflufen) in the Gazetta Ufficiale removes the last ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Swarm was formed in 2022 and has now emerged with Martin Olin – previously chief executive of BerGenBio and Symphogen – at ...

Chinese biotech Ascentage Pharma has taken the first US biotech initial public offering (IPO) of 2025 over the finish line, ...

Evolution and innovation are critical to the field of life sciences, with each year bringing new challenges and breakthroughs ...

The pharma group has pledged up to £50 million ($62.5 million) in funding over three years for the initiative, which builds ...

Pfizer has agreed to pay $60 million to resolve allegations brought by the US government that its Biohaven Pharma subsidiary ...

Capricor Therapeutics has completed its US marketing application for deramiocel, a cell therapy the US biotech hopes will become the first approved treatment for cardiomyopathy associated with ...

So far, advanced therapy developers have been focusing on partnerships with specific hospitals for collecting patient cellular materials, and there are long-term concerns over the ability for the ...

This month, we explore the 125-year-old history of Abbott Laboratories and its most significant milestone to date – the creation of its own independent company, AbbVie. In 1888, a 30-year-old ...

Drug development is a high-stakes, high-cost endeavour. Every new drug entering clinical trials requires careful decision-making, particularly regarding trial design and resource allocation.

Verona Pharma has blockbuster hopes for its recently approved drug for chronic obstructive pulmonary disorder (COPD), and preliminary sales figures for the drug suggest it is heading in the right ...